Key result
Patients with arterial or venous thrombosis had a significantly higher incidence of hyperhomocysteinemia compared to controls (55% vs 22%; OR 4.521; P<0.001).
Why the study?
Are plasma homocysteine levels and MTHFR 677 genotype associated with arterial and venous thrombosis?
Case-Control (n=130)
No
Are plasma homocysteine levels and MTHFR 677 genotype associated with arterial and venous thrombosis?
Plasma homocysteine levels are significantly elevated in patients with thrombosis compared to controls, suggesting that measuring homocysteine has greater clinical utility than MTHFR 677 genotyping for thrombosis risk assessment.
AIM: To determine the differences in plasma homocysteine levels between three MTHFR 677 genotype subgroups in patients with thrombosis and in controls, as well as between patients with thrombosis and controls with the same MTHFR 677 genotype. METHODS: This case-control study was conducted in Clinical Center of Vojvodina, Novi Sad, from June to December 2011. We included 65 patients with either arterial or venous thrombosis (mean age, 40.97 ± 11.38 years) and 65 controls with no history or clinical evidence of any thrombotic event (mean age, 41.23 ± 11.12 years). Patients and controls were age- and sex-matched. RESULTS: In comparison with controls, thrombotic patients had significantly higher homocysteine levels (12.81 ± 4.94 µmol/L vs 9.82 ± 3.68 µmol/L; P<0.001) and significantly higher incidence of hyperhomocysteinemia (55% vs 22%; P<0.001; odds ratio [OR]=4.521). There were no significant differences in homocysteine levels between homozygous carriers, heterozygous carriers, and non-carriers of the MTHFR 677 mutation in either thrombotic patients (12.97 ± 5.40 µmol/L vs 12.55 ± 5.71 µmol/L vs 13.27 ± 1.71 µmol/L; P=0.100) or controls (10.07±2.50 µmol/L vs 10.25 ± 4.84 µmol/L vs 9.20 ± 2.44 µmol/L; P=0.651). However, in comparison with controls, homozygous carriers in thrombotic patient group did not have significantly higher levels of homocysteine (12.97 ± 5.40 µmol/L vs 10.07 ± 2.50 µmol/L; P=0.072), but heterozygous carriers (12.55 ± 5.71 µmol/L vs 10.25 ± 4.84 µmol/L; P=0.020) and non-carriers (13.27 ± 1.71 µmol/L vs 9.20 ± 2.44 µmol/L; P<0.001) did. There was no significant difference in homocysteine levels between patients with arterial and venous thrombosis (12.76 ± 3.60 µmol/L vs 12.86 ± 5.51 µmol/L; P=0.990) and between patients with one thrombotic event and those with recurrent thrombotic events (12.14 ± 3.20 µmol/L vs 15.25 ± 8.51 µmol/L; P=0.254). CONCLUSION: Plasma homocysteine levels have a greater clinical significance in the prevention of thrombosis and managing its complications than MTHFR 677 genotyping.
No takes yet. Share an insight, caveat, or question.
Vučković et al. (2013) conducted a case-control in Arterial and venous thrombosis (n=130). Arterial or venous thrombosis vs. Controls without thrombosis was evaluated on Incidence of hyperhomocysteinemia (OR 4.521, p=<0.001). Patients with arterial or venous thrombosis had a significantly higher incidence of hyperhomocysteinemia compared to controls (55% vs 22%; OR 4.521; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: